List view / Grid view
AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis…
AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA® (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.1
"These data suggest that adalimumab-treated patients were able to reduce…
24 October 2012 | By Abbott
"These data suggest that adalimumab-treated patients were able to reduce steroid usage..."
Results from a post-hoc sub-analysis...
23 October 2012 | By Abbott
Results from a post-hoc sub-analysis...
First Phase 3 study to evaluate an anti-TNF in patients…
6 June 2012 | By Abbott
First Phase 3 study to evaluate an anti-TNF in patients with non-radiographic axial spondyloarthritis...
Abbott announced results from two long-term, open-label studies...
6 June 2012 | By Abbott
Abbott announced results from two long-term, open-label studies...
Abbott today announced the initiation of two Phase 3 clinical…
Abbott today announced the initiation of two Phase 3 clinical trials designed to evaluate the safety and efficacy of an investigational use of HUMIRA® (adalimumab) in adult patients with moderate to severe hidradenitis suppurativa (HS).
